Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Tomocube Inc. (475960:KRX), powered by AI.
Tomocube Inc. is currently trading at ₩39,950. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Tomocube Inc. on Alpha Lenz.
Tomocube Inc.'s P/E ratio is -111.2.
“Tomocube Inc. trades at a P/E of -111.2 (undervalued) with modest ROE of -11.9%. 3Y revenue CAGR of 82.1% highlights clear growth momentum.”
Ask for details →Tomocube Inc. is a prominent company in the field of biotechnology and medical imaging. The firm specializes in developing advanced imaging solutions that provide three-dimensional holographic visualization and quantitative analysis of living cells. This technology is pivotal for researchers and healthcare professionals as it offers a non-invasive and detailed view of cell structures and functions, enabling better understanding and research into cellular processes and diseases. Tomocube's products are used extensively in the life sciences and medical research sectors, impacting fields such as oncology, neurology, and pharmacology. By offering cutting-edge tools for cell analysis, Tomocube Inc. plays a crucial role in advancing medical research and contributing to the development of new therapies and diagnostics. The company's innovative approach not only highlights its importance in the biotech industry but also underscores its potential to influence the future of health technology.
“Tomocube Inc. trades at a P/E of -111.2 (undervalued) with modest ROE of -11.9%. 3Y revenue CAGR of 82.1% highlights clear growth momentum.”
Ask for details →Tomocube Inc. (ticker: 475960) is a company listed on KRX in the Healthcare sector (Biotechnology). Market cap is $534.7B.
The current price is ₩39,950 with a P/E ratio of -111.16x and P/B of 13.78x.
ROE is -11.91% and operating margin is -49.25%. Annual revenue is $11.3B.